Seoul, South Korea, December 11, 2020 —The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), a proprietary product of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), has received registration approval from the Ministry of Food and Drug Safety of Korea (MFDS).
Firehawk Liberty™ is the latest generation of the Firehawk line developed by MicroPort®, which also includesthe Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®) – a drug-eluting stent (DES) featuring strut in-groove coating and precision target drug-releasing patent technology. Firehawk® combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy. It allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, which ensures the effectiveness of the drug while significantly reducing the drug loading.
While retaining some features of Firehawk® stent—such as targeted drug-release—Firehawk Liberty™ uses an innovative stent balloon technology to optimize expansion performance, thus further optimizing the crossability and vessel wall apposition.
The approval of the Firehawk Liberty™ further expands the coronary intervention product line of MicroPort® in South Korea. It also increases the influence and market share of MicroPort® in the local market, as the Firehawk® Rapamycin Target Eluting Coronary Stent System, the Firefighter™, the Firefighter™ NC PTCA Balloon Dilatation Catheter and other MicroPort® products continue to gain trust and acceptance of surgeons and patients in South Korea. In the future, MicroPort® will continue to deepen its reach in the Korean market and provide quality, inclusive and integrated solutions for patients in the country.